Oculis announced that its Phase 3 DIAMOND trials for OCS-01 eye drops in diabetic macular edema did not meet the primary endpoint of improved visual acuity after 52 weeks. However, the treatment showed significant and lasting reduction in retinal thickness, a secondary measure. The drug was well tolerated with no unexpected side effects. Oculis will not pursue FDA approval for OCS-01 for this condition but will focus on other drug candidates, including Privosegtor for optic nerve disorders and Licaminlimab for dry eye disease. The company maintains strong financial health with cash to fund operations through late 2029.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
China's $1.39 trillion program to clean up hidden local government debt is succeeding in reducing off-book borrowing but is causing austerity-like effects. Local governments, key drivers of infrastructure spending and economic growth, are cutting bac...
In Q2 2026, top contributors to growth included Taiwan Semiconductor Manufacturing, Alphabet, United Rentals, Apple, and Visa. Alphabet’s Google Search and Cloud segments showed robust revenue growth of 19% and 63%, respectively, boosting operating i...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
BlackRock reported strong Q2 results with net inflows of $192 billion, pushing assets under management (AUM) to a record $15.3 trillion. The firm's ETF business showed strong momentum, supported by new product launches and inclusion in Trump accounts...
